A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients

Clinical Therapeutics

Volumn 20, Issue 3, 1998, Pages 467-476

  Diaz Martinez, Alejandro ^a   Benassinni, Oscar ^b   Ontiveros, Alfonso ^c   Gonzalez, Salvador ^d   Salin, Rafael ^e   Basquedano, Gaspar ^f   Martinez, Rene A ^g,h  

^a Fed Mexicana Sociedades Pro S   (Mexico)

^b State of Sonora   (Mexico)

^c HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^d Hospital Psiquiatrico San Rafael   (Mexico)

^e HOSPITAL PSIQUIÁTRICO FRAY BERNARDINO ÁLVAREZ   (Mexico)

^f U Invest y Psicofarmacologia Clin   (Mexico)

^g Molecular Biology Laboratory   (Mexico)

^h Col San Andres Atoto ^*  (Mexico)

Author keywords

Clinical study; Fluoxetine; Major depression; Venlafaxine

Indexed keywords

FLUOXETINE; VENLAFAXINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTPATIENT CARE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SOMNOLENCE; STATISTICAL ANALYSIS; TREMOR; VERTIGO; XEROSTOMIA;

EID: 0031901173     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80056-8     Document Type: Article

References (25)

1. Artigas F. Selective serotonin/noradrenaline reuptake inhibitors (SNRIs). Pharmacology and therapeutic potential in the treatment of depressive disorders. CNS Drugs. 1995;4:79-89.
2. Clerc GE, Ruimy P, Verdeau-Pailles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol. 1994;9:138-143.
3. Dierick M, Ravizza L, Realini R, Martin A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuro-Psychopharmacol Biol Psychiatry. 1996; 20:57-71.
4. Cunningham LA, Borison RL, Carman JS, et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol. 1994;14:99-106.
5. Lecrubier Y, Moon CAL, Schifano F, et al. Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatr Scand. 1997;95:485-493.
6. Schweizer E, Feighner J, Mandos L, Rickels K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry. 1994;55:104-108.
7. Tylee A, Bowden M, Reynolds A, et al. A double-blind, randomised, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe depression in general practice. Prim Care Psychiatry. 1997;3:51-58.
8. Guelfi JD, White C, Hackett D, et al. Effectiveness of venlafaxine in patients hospitalized with major depression and melancholia. J Clin Psychiatry. 1995;56: 450-458.
9. Khan A, Rudolph R, Baumel B, et al. Venlafaxine in depressed geriatric outpatients: An open-label clinical study. Psychopharmacol Bull. 1995;31:753-758.
10. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed rev. Washington, DC: American Psychiatric Press; 1987.
11. Hamilton MA. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
12. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134: 382-389.
13. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. DHEW Pub. No. (ADM)76-338. Rockville, Md: National Institutes of Mental Health; 1976.
14. Derogatis LR, Lipman RS, Rickels K, et al. The Hopkins Symptom Checklist (HSCL): A self-report symptom inventory. Behav Sci. 1974;19:1-15.
15. Entsuah R, Upton GV, Rudolph R. Efficacy of venlafaxine treatment in depressed patients with psychomotor retardation or agitation: A meta-analysis. Hum Psychopharmacol. 1995;10:195-200.
16. Mahapatra S, Hackett D. A randomized, double-blind, parallel-group comparison of venlafaxine and dothiepin in geriatric patients with major depression, Int J Clin Pract. 1997;51:209-213.
17. Preskorn S. Pharmacotherapeutic profile of venlafaxine. Eur Psychiatry. 1997;12 (Suppl 4):285S-294S.
18. Gram LF. Fluoxetine. NEJM. 1994;331: 1354-1361.
19. Dornseif BE, Dunlop SR, Potvin JH, Wernicke JF. Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull. 1989;25:71-79.
20. Preskorn SH, Lane RM. Sertraline 50 mg: Optimal dose in the treatment of depression. Int Clin Psychopharmacol. 1995;10: 129-141.
21. Danish University Antidepressant Group. Citalopram: Clinical effect profile in comparison with clomipramine: A controlled multicenter study. Psychopharmacology. 1986;90:131-138.
22. Danish University Antidepressant Group. Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord. 1990;18:289-299.
23. Anderson IM, Tomenson BM. The efficacy of selective serotonin re-uptake inhibitors in depression: A meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol. 1994;8:238-249.
24. Roose SP, Glassman AH, Attia E. Comparative efficacy of the selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry. 1994;151:1735-1739.
25. Ereshefsky L. Drug-drug interactions involving antidepressants: Focus on venlafaxine. J Clin Psychopharmacol. 1996;16 (Suppl 2):37S-53S.